{"id":"F2024L00484","name":"Statement of Principles concerning myasthenia gravis (Balance of Probabilities) (No. 33 of 2024)","slug":"statement-of-principles-concerning-myasthenia-gravis-balance-of-probabilities-no-33-of-2024","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"in_force","isInForce":true,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":442371,"registerId":"F2024L00484-fast-fetch-1775957393911","compilationNumber":null,"startDate":"2026-04-12","status":"InForce","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"1","sectionType":"section","heading":"Statement of Principles concerning myasthenia gravis (Balance of Probabilities) (No. 33 of 2024)","content":"---\nmeta-content-style-type: text/css\nmeta-content-type: application/xhtml+xml; charset=utf-8\n---\n\n?xml version=\"1.0\" encoding=\"utf-8\" standalone=\"no\"?>\n\n\n\n \n\nStatement of Principles\n\nconcerning\n\nMYASTHENIA GRAVIS (Balance of Probabilities)\n\n(No. 33 of 2024)\n\nThe Repatriation Medical Authority determines the following Statement of Principles under subsection 196B(3) of the Veterans' Entitlements Act 1986.\n\n \n\nDated 26 April 2024.\n\n \n\n \n\n \n\n \n\n \n\n|
|\n| --- |\n|
Professor Terence Campbell AM
Chairperson
by and on behalf of
The Repatriation Medical Authority |\n\n\n \n\n \n\n\nContents\n\n1 Name\n\n2 Commencement\n\n3 Authority\n\n4 Repeal\n\n5 Application\n\n6 Definitions\n\n7 Kind of injury, disease or death to which this Statement of Principles relates\n\n8 Basis for determining the factors\n\n9 Factors that must exist\n\n10 Relationship to service\n\n11 Factors referring to an injury or disease covered by another Statement of Principles\n\nSchedule 1 - Dictionary\n\n1 Definitions\n\n \n\n\n\n\n1 Name\n\nThis is the Statement of Principles concerning myasthenia gravis (Balance of Probabilities) (No. 33 of 2024).\n\n2 Commencement\n\n This instrument commences on 28 May 2024.\n\n3 Authority\n\nThis instrument is made under subsection 196B(3) of the Veterans' Entitlements Act 1986.\n\n4 Repeal\n\nThe Statement of Principles concerning myasthenia gravis No. 76 of 2015 (Federal Register of Legislation No. F2015L00908) made under subsection 196B(3) of the VEA is repealed.\n\n5 Application\n\nThis instrument applies to a claim to which section 120B of the VEA or section 339 of the Military Rehabilitation and Compensation Act 2004 applies.\n\n6 Definitions\n\nThe terms defined in the Schedule 1 - Dictionary have the meaning given when used in this instrument.\n\n7 Kind of injury, disease or death to which this Statement of Principles relates\n\n(1) This Statement of Principles is about myasthenia gravis and death from myasthenia gravis.\n\nMeaning of myasthenia gravis\n\n(2) For the purposes of this Statement of Principles, myasthenia gravis:\n\n(a) means an autoimmune neuromuscular disorder due to impaired neuromuscular signal transmission as a result of an immunologic process directed at acetylcholine receptors or other proteins of the postsynaptic membrane of the neuromuscular junction and characterised by weakness and fatigability of skeletal muscles; and\n\n(b) excludes myasthenic syndromes such as congenital myasthenia gravis and Lambert-Eaton myasthenic syndrome.\n\nNote: Examples of clinical worsening might include:\n\n(a) a persistent increase in the weakness of muscles already affected or when additional muscles are affected (such as the development of upper limb weakness when previously only ocular muscles were affected);\n\n(b) a persistent increase in the requirement for treatment of myasthenia gravis, which may include increasing the dose of a particular drug, the addition of new drugs, the introduction of plasma exchange or intravenous immunoglobulin, or the need for hospitalisation; and\n\n(c) an episode of severe myasthenia gravis resulting in myasthenic crisis or death.\n\n(3) While myasthenia gravis attracts ICD‑10‑AM code G70.0, in applying this Statement of Principles the meaning of myasthenia gravis is that given in subsection (2).\n\n(4) For subsection (3), a reference to an ICD-10-AM code is a reference to the code assigned to a particular kind of injury or disease in The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM), Tenth Edition, effective date of 1 July 2017, copyrighted by the Independent Hospital Pricing Authority, ISBN 978-1-76007-296-4.\n\nDeath from myasthenia gravis\n\n(5) For the purposes of this Statement of Principles, myasthenia gravis, in relation to a person, includes death from a terminal event or condition that was contributed to by the person's myasthenia gravis.\n\nNote: terminal event is defined in the Schedule 1 – Dictionary.\n\n8 Basis for determining the factors\n\nOn the sound medical‑scientific evidence available, the Repatriation Medical Authority is of the view that it is more probable than not that myasthenia gravis and death from myasthenia gravis can be related to relevant service rendered by veterans or members of the Forces under the VEA, or members under the MRCA.\n\nNote: MRCA, relevant service and VEA are defined in the Schedule 1 – Dictionary.\n\n9 Factors that must exist\n\nAt least one of the following factors must exist before it can be said that, on the balance of probabilities, myasthenia gravis or death from myasthenia gravis is connected with the circumstances of a person's relevant service:\n\n(1) being treated with one of the following medications within the 3 months before clinical onset:\n\n(a) alemtuzumab;\n\n(b) chloroquine;\n\n(c) etanercept;\n\n(d) gabapentin;\n\n(e) HMG coenzyme A reductase inhibitors (statins);\n\n(f) hydroxychloroquine;\n\n(g) immune checkpoint inhibitors including ipilimumab, nivolumab, pembrolizumab, atexolizumab, avelumab, dostarlimab, and durvalumab;\n\n(h) interferon alpha;\n\n(i) lithium carbonate;\n\n(j) penicillamine;\n\n(k) phenytoin; \n\n(l) trimethadione;\n\n(2) being treated with one of the following medications at the time of the clinical worsening:\n\n(a) acetazolamide;\n\n(b) alemtuzumab\n\n(c) amantadine;\n\n(d) amitriptyline;\n\n(e) anaesthetic agents;\n\n(f) antibiotics;\n\n(g) beta-blockers;\n\n(h) botulinum toxin;\n\n(i) calcium channel blockers;\n\n(j) carbamazepine;\n\n(k) chloroquine;\n\n(l) chlorpromazine;\n\n(m) cocaine;\n\n(n) colchicine;\n\n(o) diphenhydramine;\n\n(p) droperidol;\n\n(q) echothiophate;\n\n(r) ementine;\n\n(s) ergometrine;\n\n(t) etafenone;\n\n(u) etanercept\n\n(v) ethosuximide;\n\n(w) gabapentin;\n\n(x) haloperidol;\n\n(y) HMG coenzyme A reductase inhibitors (statins);\n\n(z) hydroxychloroquine;\n\n(aa) imipramine;\n\n(bb) immune checkpoint inhibitors;\n\n(cc) interferon alpha;\n\n(dd) interleukin-2;\n\n(ee) levonorgestrel implant;\n\n(ff) lithium carbonate;\n\n(gg) magnesium sulphate;\n\n(hh) mefloquine;\n\n(ii) nicotine transdermal patch;\n\n(jj) paraldehyde;\n\n(kk) potassium losing diuretics;\n\n(ll) penicillamine;\n\n(mm) peruvoside;\n\n(nn) phenytoin;\n\n(oo) procainamide;\n\n(pp) proguanil;\n\n(qq) propafenone;\n\n(rr) pyrantel pamoate;\n\n(ss) quinidine;\n\n(tt) quinine;\n\n(uu) ribavirin;\n\n(vv) sedative analgesics including barbiturates, muscle relaxants, narcotics and tranquillisers;\n\n(ww) systemic corticosteroids;\n\n(xx) thyroid hormone replacement therapy;\n\n(yy) tiopronin;\n\n(zz) trientine;\n\n(aaa) trihexyphenidyl;\n\n(bbb) trimethadione;\n\n(ccc) trimethaphan;\n\n(3) having an injection of an iodinated radiological contrast agent within the 24 hours before clinical worsening;\n\nNote: Iodinated contrast agents include but are not limited to iothalamic acid, diatrizoate meglumine and diatrizoate sodium.\n\n(4) undergoing haematopoietic stem cell transplantation before clinical onset or clinical worsening;\n\n(5) being pregnant within the 6 weeks before clinical worsening;\n\n(6) having an infection with any of the following conditions in the 2 months before clinical worsening:\n\n(a) pneumonia;\n\n(b) influenza; \n\n(c) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection;\n\n(d) upper respiratory tract infection;\n\n(e) urinary tract infection;\n\n(f) gastrointestinal infection;\n\n(g) septicaemia;\n\n(7) having major surgery or major trauma within the 2 months before clinical worsening;\n\n(8) receiving the ChAdOx1 nCoV-19 vaccine within the 2 months before clinical onset or clinical worsening;\n\n(9) experiencing a category 1A stressor within the 2 weeks before clinical worsening;\n\nNote: category 1A stressor is defined in the Schedule 1 – Dictionary.\n\n(10) experiencing a category 1B stressor within the 2 weeks before clinical worsening;\n\nNote: category 1B stressor is defined in the Schedule 1 – Dictionary.\n\n(11) experiencing a category 2 stressor within the 1 year before clinical onset;\n\nNote 1: A category 2 stressor can arise in a variety of circumstances connected with service. Such circumstances can arise during the course of service, as a result of separation from service and the conditions associated with that separation, and in the transition to civilian life in the years following separation.\n\nNote 2: category 2 stressor is defined in the Schedule 1 - Dictionary.\n\n(12) having depressive disorder or anxiety disorder, sufficient to warrant ongoing management which may involve regular visits (for example, at least monthly) to a psychiatrist, counsellor or general practitioner, within the 6 months before clinical worsening;\n\nNote: To warrant ongoing management does not require that any actual management was provided.\n\n(13) inability to obtain appropriate clinical management for myasthenia gravis before clinical worsening.\n\n10 Relationship to service\n\n(1) The existence in a person of any factor referred to in section 9, must be related to the relevant service rendered by the person.\n\n(2) The clinical worsening aspects of factors set out in section 9 apply only to material contribution to, or aggravation of, myasthenia gravis where the person's myasthenia gravis was suffered or contracted before or during (but did not arise out of) the person's relevant service.\n\n11 Factors referring to an injury or disease covered by another Statement of Principles\n\nIn this Statement of Principles:\n\n(1) if a factor referred to in section 9 applies in relation to a person; and\n\n(2) that factor refers to an injury or disease in respect of which a Statement of Principles has been determined under subsection 196B(3) of the VEA;\n\nthen the factors in that Statement of Principles apply in accordance with the terms of that Statement of Principles as in force from time to time.\n\n \n\n \n\nSchedule 1 - Dictionary \n\nNote: See Section 6\n\n1 Definitions\n\nIn this instrument:\n\ncategory 1A stressor means one of the following severe traumatic events:\n\n(a) experiencing a life-threatening event;\n\n(b) being subject to a serious physical attack or assault including rape and sexual molestation; or\n\n(c) being threatened with a weapon, being held captive, being kidnapped, or being tortured.\n\n category 1B stressor means one of the following severe traumatic events:\n\n(a) killing or maiming a person;\n\n(b) being a witness to a person being killed or critically injured;\n\n(c) being a witness to atrocities inflicted on another person;\n\n(d) participating in the clearance of a corpse or a critically injured casualty; or\n\n(e) viewing a corpse or a critically injured casualty as a witness.\n\nNote: corpse and witness are defined in the Schedule 1 – Dictionary.\n\n category 2 stressor means one of the following negative life events, the effects of which are chronic in nature and cause the person to feel on-going distress, concern or worry:\n\n(a) being socially isolated and unable to maintain friendships or family relationships, due to physical location, ethnicity, sexuality, disability, or medical or psychiatric illness;\n\n(b) experiencing a problem with a long-term relationship including the break-up of a close personal relationship, the need for marital or relationship counselling, marital separation, or divorce;\n\n(c) having concerns in the work or school environment including on-going disharmony with fellow work or school colleagues, perceived lack of social support within the work or school environment, perceived lack of control over tasks performed and stressful workloads, or experiencing bullying in the workplace or school environment;\n\n(d) experiencing serious legal issues including being detained or held in custody, on-going involvement with the police concerning violations of the law, or court appearances associated with personal legal problems;\n\n(e) having severe financial hardship including loss of employment, long periods of unemployment, foreclosure on a property, or bankruptcy; or\n\n(f) having a family member or close friend experience a major deterioration in their health.\n\n corpse means the human remains or body parts of one or more persons who have met a violent or horrific death.\n\nNote: Examples of a violent or horrific death may include death due to suicide, gunshot, improvised explosive devices, natural and technological disasters, terrorist attacks or motor vehicle accidents. Seeing a closed body bag or viewing a body in an open-casket coffin are excluded from this definition.\n\n MRCA means the Military Rehabilitation and Compensation Act 2004.\n\n myasthenia gravis—see subsection 7(2).\n\n relevant service means:\n\n(a) eligible war service (other than operational service) under the VEA;\n\n(b) defence service (other than hazardous service and British nuclear test defence service) under the VEA; or\n\n(c) peacetime service under the MRCA.\n\nNote: MRCA and VEA are also defined in the Schedule 1 - Dictionary.\n\n terminal event means the proximate or ultimate cause of death and includes the following:\n\n(a) pneumonia;\n\n(b) respiratory failure;\n\n(c) cardiac arrest;\n\n(d) circulatory failure; or\n\n(e) cessation of brain function.\n\n VEA means the Veterans' Entitlements Act 1986.\n\n witness means a person who experiences an incident at the time it occurs and can give direct evidence of it. This excludes persons exposed only to public broadcasting or mass media coverage of the incident.\n\n \n\n \n","sortOrder":0}],"analysis":{"kimi_summary":{"content_quality":"ok","complexity_score":5,"scope_assessment":{"changed":false,"description":"This instrument maintains the established scope of Repatriation Medical Authority Statements of Principles. It updates the 2015 version with contemporary medical evidence (adding COVID-19, AstraZeneca vaccine, and newer immunotherapies) but does not expand beyond the traditional purpose of defining service-connected causation for a specific disease. The structure and limitation to balance-of-probabilities claims for non-operational service remains consistent with the legislative framework established by the Veterans' Entitlements Act 1986."},"complexity_factors":["Moderate length (approximately 1,500 words) with clear structural divisions","13 distinct causal factors with varying timeframes (24 hours to 1 year lookback periods)","Extensive medication lists (12 drugs for onset, 55 drugs for worsening) requiring cross-referencing against medical records","Nested definitions in Schedule 1 with 9 defined terms including complex stressor hierarchies (Category 1A, 1B, and 2)","Conditional logic in section 10 limiting clinical worsening claims to pre-existing conditions not arising from service","Cross-reference mechanism in section 11 linking to other Statements of Principles for compound conditions","Medical terminology requiring specialist knowledge (ICD-10-AM codes, immunologic processes, neuromuscular junction)","Specific evidentiary thresholds (e.g., 'sufficient to warrant ongoing management' for mental health conditions)"],"plain_english_summary":"This instrument sets the medical test for linking myasthenia gravis to non‑operational Australian defence service for compensation claims, replacing the 2015 guidance with updated evidence. It lists 13 specific connection factors and applies the \"balance of probabilities\" standard.\n\nIt affects veterans and current/former defence members claiming under the VEA or MRCA. As the gatekeeper for entitlement, it notably adds modern triggers like COVID‑19 infection and the AstraZeneca vaccine to the factors considered."},"flash_summary_failed":{"failed":true,"reason":"Unauthenticated. Configure AI_GATEWAY_API_KEY or use a provider module. Learn more: https://ai-sdk.dev/unauthenticated-ai-gateway","source":"analysis-cron"},"flash_summary":{"complexity_score":6,"scope_assessment":{"changed":false,"description":"The instrument repeals the 2015 Statement (s4) but continues to apply to claims under the same statutory claim routes (VEA s120B; MRCA s339) (s5). The primary changes are to the medical factors, timing windows and definitions used to establish service connection rather than to the population of claimants covered."},"complexity_factors":["Extensive, enumerated lists of specific medications with differing timing windows for onset and clinical worsening (s9(1)–(3)).","Medical-scientific causal standard framed as 'balance of probabilities' combined with clinical onset vs clinical worsening distinctions (s8; s9(2); s10(2)).","Cross-references to other Statements of Principles and to an external classification (ICD‑10‑AM) affecting diagnosis coding (s4; s7(3)–(4); s11).","Nuanced psychosocial definitions and multiple stressor categories with chronicity and examples (Schedule 1: category 1A, 1B, 2).","Requirement that any listed factor be shown to be related to the person's relevant service, and limits on material contribution vs arising out of service (s10(1)–(2)).","Application confined to claims under specific statutory provisions (VEA s120B and MRCA s339) but requiring factual and medical enquiries (s5).","Repeal of the prior 2015 Statement may necessitate reassessment of prior determinations or claims processes (s4).","Key interpretive terms (e.g. 'terminal event', 'relevant service', 'witness') are defined in the Schedule and materially affect application (Schedule 1)."],"plain_english_summary":"This Statement of Principles replaces the 2015 version and sets the medical criteria by which myasthenia gravis (and death from it) can be linked to a veteran's or member’s relevant service on the balance of probabilities. It applies to claims under the VEA s120B and MRCA s339.\n\nIt lists required factors and timing windows (recent exposure to specified drugs, infections, surgery, vaccination, pregnancy, stressors, transplant, or inability to access care) and requires medical evidence that those factors were related to the person's relevant service."}},"importantCases":[],"_links":{"self":"/api/acts/statement-of-principles-concerning-myasthenia-gravis-balance-of-probabilities-no-33-of-2024","history":"/api/acts/statement-of-principles-concerning-myasthenia-gravis-balance-of-probabilities-no-33-of-2024/history","analysis":"/api/acts/statement-of-principles-concerning-myasthenia-gravis-balance-of-probabilities-no-33-of-2024/analysis","conflicts":"/api/acts/statement-of-principles-concerning-myasthenia-gravis-balance-of-probabilities-no-33-of-2024/conflicts","importantCases":"/api/acts/statement-of-principles-concerning-myasthenia-gravis-balance-of-probabilities-no-33-of-2024/important-cases","documents":"/api/acts/statement-of-principles-concerning-myasthenia-gravis-balance-of-probabilities-no-33-of-2024/documents"}}